These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 23537520)

  • 1. Association KRAS G13D tumor mutated outcome in patients with chemotherapy refractory metastatic colorectal cancer treated with cetuximab.
    Tural D; Selcukbiricik F; Erdamar S; Ozkurt CU; Yanmaz T; Mandel NM; Serdengeçti S
    Hepatogastroenterology; 2013; 60(125):1035-40. PubMed ID: 23537520
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of KRAS G13D tumor mutations with outcome in patients with metastatic colorectal cancer treated with first-line chemotherapy with or without cetuximab.
    Tejpar S; Celik I; Schlichting M; Sartorius U; Bokemeyer C; Van Cutsem E
    J Clin Oncol; 2012 Oct; 30(29):3570-7. PubMed ID: 22734028
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab.
    De Roock W; Jonker DJ; Di Nicolantonio F; Sartore-Bianchi A; Tu D; Siena S; Lamba S; Arena S; Frattini M; Piessevaux H; Van Cutsem E; O'Callaghan CJ; Khambata-Ford S; Zalcberg JR; Simes J; Karapetis CS; Bardelli A; Tejpar S
    JAMA; 2010 Oct; 304(16):1812-20. PubMed ID: 20978259
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Influence of KRAS p.G13D mutation in patients with metastatic colorectal cancer treated with cetuximab.
    Gajate P; Sastre J; Bando I; Alonso T; Cillero L; Sanz J; Caldés T; Díaz-Rubio E
    Clin Colorectal Cancer; 2012 Dec; 11(4):291-6. PubMed ID: 22537608
    [TBL] [Abstract][Full Text] [Related]  

  • 5. KRAS p.G13D mutation and codon 12 mutations are not created equal in predicting clinical outcomes of cetuximab in metastatic colorectal cancer: a systematic review and meta-analysis.
    Mao C; Huang YF; Yang ZY; Zheng DY; Chen JZ; Tang JL
    Cancer; 2013 Feb; 119(4):714-21. PubMed ID: 22972628
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cetuximab-based or bevacizumab-based first-line treatment in patients with KRAS p.G13D-mutated metastatic colorectal cancer: a pooled analysis.
    Modest DP; Reinacher-Schick A; Stintzing S; Giessen C; Tannapfel A; Laubender RP; Brodowicz T; Knittelfelder R; Vrbanec D; Schmiegel W; Heinemann V; Zielinski CC
    Anticancer Drugs; 2012 Jul; 23(6):666-73. PubMed ID: 22441566
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of genetic profiles on the efficacy of anti-EGFR antibodies in metastatic colorectal cancer with KRAS mutation.
    Kishiki T; Ohnishi H; Masaki T; Ohtsuka K; Ohkura Y; Furuse J; Sugiyama M; Watanabe T
    Oncol Rep; 2014 Jul; 32(1):57-64. PubMed ID: 24839940
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of KRAS mutations in predicting the efficacy of cetuximab-plus-irinotecan therapy in irinotecan-refractory Korean metastatic colorectal cancer patients.
    Sohn BS; Kim TW; Lee JL; Ryu MH; Chang HM; Kang YK; Park HS; Na YS; Jang SJ; Kim JC; Lee JS
    Oncology; 2009; 77(3-4):224-30. PubMed ID: 19738388
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Activating KRAS mutations and overexpression of epidermal growth factor receptor as independent predictors in metastatic colorectal cancer patients treated with cetuximab.
    Yen LC; Uen YH; Wu DC; Lu CY; Yu FJ; Wu IC; Lin SR; Wang JY
    Ann Surg; 2010 Feb; 251(2):254-60. PubMed ID: 20010090
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of Fc{gamma}RIIa-Fc{gamma}RIIIa polymorphisms and KRAS mutations on the clinical outcome of patients with metastatic colorectal cancer treated with cetuximab plus irinotecan.
    Bibeau F; Lopez-Crapez E; Di Fiore F; Thezenas S; Ychou M; Blanchard F; Lamy A; Penault-Llorca F; Frébourg T; Michel P; Sabourin JC; Boissière-Michot F
    J Clin Oncol; 2009 Mar; 27(7):1122-9. PubMed ID: 19164213
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical outcome of Japanese metastatic colorectal cancer patients harbouring the KRAS p.G13D mutation treated with cetuximab + irinotecan.
    Bando H; Yoshino T; Yuki S; Shinozaki E; Nishina T; Kadowaki S; Yamazaki K; Kajiura S; Tsuchihara K; Fujii S; Yamanaka T; Ohtsu A
    Jpn J Clin Oncol; 2012 Dec; 42(12):1146-51. PubMed ID: 23071293
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Detection of KRAS oncogene in peripheral blood as a predictor of the response to cetuximab plus chemotherapy in patients with metastatic colorectal cancer.
    Yen LC; Yeh YS; Chen CW; Wang HM; Tsai HL; Lu CY; Chang YT; Chu KS; Lin SR; Wang JY
    Clin Cancer Res; 2009 Jul; 15(13):4508-13. PubMed ID: 19549774
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PTEN expression and KRAS mutations on primary tumors and metastases in the prediction of benefit from cetuximab plus irinotecan for patients with metastatic colorectal cancer.
    Loupakis F; Pollina L; Stasi I; Ruzzo A; Scartozzi M; Santini D; Masi G; Graziano F; Cremolini C; Rulli E; Canestrari E; Funel N; Schiavon G; Petrini I; Magnani M; Tonini G; Campani D; Floriani I; Cascinu S; Falcone A
    J Clin Oncol; 2009 Jun; 27(16):2622-9. PubMed ID: 19398573
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer.
    Di Nicolantonio F; Martini M; Molinari F; Sartore-Bianchi A; Arena S; Saletti P; De Dosso S; Mazzucchelli L; Frattini M; Siena S; Bardelli A
    J Clin Oncol; 2008 Dec; 26(35):5705-12. PubMed ID: 19001320
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Effect of KRAS mutation on efficacy of Cetuximab combined with chemotherapy in advanced colorectal cancer patients].
    Pu XX; Deng YH; Xu F; Xiao J; Guo HQ; Huang H; Tian Y; He YJ; Lin TY
    Zhonghua Wei Chang Wai Ke Za Zhi; 2009 Nov; 12(6):594-7. PubMed ID: 19921572
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Analysis of PTEN, BRAF and PI3K status for determination of benefit from cetuximab therapy in metastatic colorectal cancer patients refractory to chemotherapy with wild-type KRAS.
    Tural D; Batur S; Erdamar S; Akar E; Kepil N; Mandel NM; Serdengeçti S
    Tumour Biol; 2014 Feb; 35(2):1041-9. PubMed ID: 23996432
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cetuximab plus irinotecan after irinotecan failure in elderly metastatic colorectal cancer patients: clinical outcome according to KRAS and BRAF mutational status.
    Fornaro L; Baldi GG; Masi G; Allegrini G; Loupakis F; Vasile E; Cupini S; Stasi I; Salvatore L; Cremolini C; Vincenzi B; Santini D; Tonini G; Graziano F; Ruzzo A; Canestrari E; Magnani M; Falcone A
    Crit Rev Oncol Hematol; 2011 Jun; 78(3):243-51. PubMed ID: 20619672
    [TBL] [Abstract][Full Text] [Related]  

  • 18. KRAS mutant allele-specific imbalance (MASI) assessment in routine samples of patients with metastatic colorectal cancer.
    Malapelle U; Sgariglia R; De Stefano A; Bellevicine C; Vigliar E; de Biase D; Sepe R; Pallante P; Carlomagno C; Tallini G; Troncone G
    J Clin Pathol; 2015 Apr; 68(4):265-9. PubMed ID: 25609577
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ICECREAM: randomised phase II study of cetuximab alone or in combination with irinotecan in patients with metastatic colorectal cancer with either KRAS, NRAS, BRAF and PI3KCA wild type, or G13D mutated tumours.
    Segelov E; Waring P; Desai J; Wilson K; Gebski V; Thavaneswaran S; Elez E; Underhill C; Pavlakis N; Chantrill L; Nott L; Jefford M; Khasraw M; Day F; Wasan H; Ciardiello F; Karapetis C; Joubert W; van Hazel G; Haydon A; Price T; Tejpar S; Tebbutt N; Shapiro J
    BMC Cancer; 2016 May; 16():339. PubMed ID: 27246726
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cetuximab plus chemotherapy as first-line treatment for metastatic colorectal cancer: effect of KRAS mutation on treatment efficacy in Taiwanese patients.
    Chen MC; Chiang FF; Wang HM
    Neoplasma; 2013; 60(5):561-7. PubMed ID: 23790176
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.